双相情感障碍患者人类白细胞抗原-B^(*)1502基因检测分析及用药风险评估  

HLA-B^(*)1502 gene detection analysis and medication risk assessment in patients with bipolar disorder

作　　者：王艳[1] 邱欣[1] WANG Yan;QIU Xin(Department of Pharmacology,Maternity and Child Health Care of Zaozhuang,Shandong Province,Zaozhuang 277100,China)

机构地区：[1]山东省枣庄市妇幼保健院药学部,山东枣庄277100

出　　处：《中国当代医药》2024年第3期4-6,12,共4页China Modern Medicine

摘　　要：目的通过检测并分析双相情感障碍(BD)患者人类白细胞抗原-B^(*)1502(HLA-B^(*)1502)基因多态性,评估拉莫三嗪诱发皮肤不良反应的风险。方法回顾性收集2019年1月至2022年8月在枣庄市妇幼保健院就诊并在初次使用拉莫三嗪前采用荧光染色原位杂交测序技术检测HLA-B^(*)1502基因型和用药指导的510例患者作为研究对象,分析其基因型与皮肤型药物不良反应发生情况。结果患者HLA-B^(*)1502基因中阳性结果的占比低于阴性结果,差异有统计学意义(P<0.05)。HLA-B^(*)1502基因阳性结果中,杂合突变型占比高于纯合突变型,差异有统计学意义(P<0.01)。结论临床在初次使用拉莫三嗪控制和治疗双相情感障碍患者的过程中,为降低拉莫三嗪诱发皮肤不良反应的风险,有必要进行HLA-B^(*)1502基因检测。Objective To detect and analyze the polymorphism of human leukocyte antigen-B^(*)1502(HLA-B^(*)1502)gene in patients with bipolar disorder(BD),and to evaluate the risk of skin adverse reactions induced by Lamotrigine.Methods A total of 510 patients who were treated in Zaozhuang Maternal and Child Health Hospital from January 2019 to August 2022 and detected HLA-B^(*)1502 genotype and medication guidance by fluorescence staining in situ hybridization sequencing before the initial use of Lamotrigine were retrospectively collected as research objects.The genotype and the occurrence of skin type adverse drug reactions were analyzed.Results The proportion of positive HLA-B^(*)1502 gene was lower than that of negative HLA-B^(*)1502 gene,and the difference was statistically significant(P<0.05).Among HLA-B^(*)1502 gene positive results,the proportion of heterozygous mutants was higher than that of homozygous mutants,and the difference was statistically significant(P<0.01).Conclusion Clinical during the initial use of Lamotrigine to control and treat patients with BD,HLA-B^(*)1502 gene testing is necessary to reduce the risk of skin adverse reactions induced by Lamotrigine.

关 键 词：双相情感障碍 拉莫三嗪 皮肤型药物不良反应 HLA-B^(*)1502 

分 类 号：R749[医药卫生—神经病学与精神病学]